A recent proposal to limit Medicare coverage for Aduhelm (aducanumab) and similar medicines to Alzheimer’s disease patients who are enrolled in clinical trials ignores current science and would drastically curtail access these therapies, UsAgainstAlzheimer’s argues. UsAgainstAlzheimer’s (UsA2), based in Washington, D.C., is founded by family members of people affecting by Alzheimer’s. Its comment letter was in response to a draft National Coverage Determination proposed by the U.S. Centers for Medicare and Medicaid Services (CMS). If enacted, the proposal…
You must be logged in to read/download the full post.
The post UsAgainstAlzheimer’s, Experts Blast Medicare’s Plan for Aduhelm appeared first on BioNewsFeeds.